April 20th, ACTC Announces third Dry AMD patient treated in Clinical trial. Robert Lanza MD, ACT's chief scientific officer stated, "We are extremely pleases with the progress being made in all three of our clinical trials here in the US and the UK. ACTC is up a little today
Geron webcast at 10:30AM today is also up. Hoping for some thing good. Please Chip say it, a deal!
Good luck in this rigged casino,
No comments:
Post a Comment